Prenetics Global Ltd (PRE) FinancialsPREPrenetics Global Ltd

Prenetics Global Ltd (PRE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics , accounting for 91.3% of total sales, equivalent to $59.06M. Another important revenue stream is Prevention . Understanding this composition is critical for investors evaluating how PRE navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Prenetics Global Ltd maintains a gross margin of 64.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -45.13%, while the net margin is -19.55%. These profitability ratios, combined with a Return on Equity (ROE) of -45.89%, provide a clear picture of how effectively PRE converts its operational activities into shareholder value.

In the context of the broader market, PRE competes directly with industry leaders such as PACH and ACGC. With a market capitalization of $348.92M, it holds a leading position in the sector. When comparing efficiency, PRE's gross margin of 64.97% stands against PACH's N/A and ACGC's N/A. Such benchmarking helps identify whether Prenetics Global Ltd is trading at a premium or discount relative to its financial performance.

Prenetics reported a total revenue of $46.5 million in Q2 2026, a significant increase from previous quarters, and raised its fiscal year 2026 revenue guidance to $220 million-$230 million, indicating strong growth potential.